Indivior PLC
LSE:INDV

Watchlist Manager
Indivior PLC Logo
Indivior PLC
LSE:INDV
Watchlist
Price: 932 GBX 1.91%
Market Cap: 1.2B GBX
Have any thoughts about
Indivior PLC?
Write Note

Indivior PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Indivior PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Indivior PLC
LSE:INDV
Additional Paid In Capital
$11m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Additional Paid In Capital
ÂŁ3.5B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Additional Paid In Capital
$35.2B
CAGR 3-Years
64%
CAGR 5-Years
35%
CAGR 10-Years
24%
Verona Pharma PLC
NASDAQ:VRNA
Additional Paid In Capital
$621.6m
CAGR 3-Years
18%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Additional Paid In Capital
$282m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Dechra Pharmaceuticals PLC
LSE:DPH
Additional Paid In Capital
ÂŁ596m
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
17%
No Stocks Found

Indivior PLC
Glance View

Market Cap
1.2B GBX
Industry
Pharmaceuticals

Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.

INDV Intrinsic Value
2 223 GBX
Undervaluation 58%
Intrinsic Value
Price

See Also

What is Indivior PLC's Additional Paid In Capital?
Additional Paid In Capital
11m USD

Based on the financial report for Jun 30, 2024, Indivior PLC's Additional Paid In Capital amounts to 11m USD.

What is Indivior PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
17%

Over the last year, the Additional Paid In Capital growth was 22%. The average annual Additional Paid In Capital growth rates for Indivior PLC have been 22% over the past three years , 17% over the past five years .

Back to Top